MENU

YMAB Stock Y-mAbs Therapeutics (YMAB, $14.81) entered Uptrend as Momentum indicator ascends above 0 level on Oct 28, 2024

A.I.dvisor
at Tickeron.com
10/29/24
Loading...
YMAB - Y-mAbs Therapeutics
Momentum signal
Bullish Trend
Odds of UP Trend
Tickeron
Momentum signal
Price: $14.81
Daily change: +$0.33 (+2.28%)
Daily volume: 149.8K
Industry: Biotechnology
This indicator may be signaling that YMAB's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 85 similar cases where YMAB's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:

Momentum Indicator for YMAB turns positive, indicating new upward trend

YMAB saw its Momentum Indicator move above the 0 level on October 28, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where YMAB advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 204 cases where YMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where YMAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for YMAB turned negative on October 31, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. YMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.954) is normal, around the industry mean (14.125). P/E Ratio (0.000) is within average values for comparable stocks, (131.373). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.394). YMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (7.519) is also within normal values, averaging (235.543).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel antibody therapeutics for oncology targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
230 Park Avenue
Phone
+1 646 885-8505
Employees
100
Web
https://www.ymabs.com